Breast Cancer

Breast Cancer

Predictors for Fear of Cancer Recurrence in Breast Cancer Patients Referred to Radiation Therapy During the COVID-19 Pandemic

The outbreak of COVID-19 pandemic has greatly impacted on RT strategy for breast cancer patients, which might lead to increased distressing psychological symptoms.

Frontiers in Oncology
Breast-Conserving Surgery Plus Radiotherapy May Yield Better Survival Than Mastectomy With or Without Radiotherapy

de Boniface et al find that breast-conserving surgery plus RT for women with breast cancer is associated with better survival vs mastectomy with or without RT in analysis adjusting for...

The ASCO Post
Real-World Survival Outcomes With Pertuzumab Plus T-DM1 for HER2-Positive Metastatic Breast Cancer

Study investigators identify real-world survival outcomes among women receiving pertuzumab and trastuzumab emtansine for stage IV HER2+ breast cancer...

The ASCO Post

Pyrotinib in the Treatment of Women With HER2-Positive Advanced Breast Cancer

This multicenter study analyzes the real-world data of women treated with pyrotinib-based therapy, aiming to describe their characteristics, treatment regimens, and to investigate...

Frontiers in Oncology
Effect of Celecoxib vs Placebo as Adjuvant Therapy on DFS Among Patients With Breast Cancer

This study examines if there is a benefit for patients who receive celecoxib as an addition to conventional therapy for women with ERBB2 (formerly HER2)–negative primary breast cancer.

JAMA Oncology
Identification of a Three-RNA Binding Proteins Signature Predicting Prognosis for Breast Cancer

In this study, investigators focused on the communal differently expressed RBPs in four subtypes of breast cancer.

Frontiers in Oncology
Is Chemotherapy Associated With Complications or Poorer Outcomes Among Women Undergoing Immediate Breast Reconstruction?

Hart et al found treatment with either neoadjuvant or adjuvant CT was not associated with an increased risk of complications or poorer patient-reported outcomes in women undergoing mastectomy...

The ASCO Post
Associations of Reproductive Breast Cancer Risk Factors With Breast Tissue Composition

Study investigators examine the associations of reproductive factors with the percentage of epithelium, stroma, and fat tissue in benign breast biopsy samples.

Breast Cancer Research
The Prognostic Relevance of HER2+ Gain in Metastatic Breast Cancer in the ChangeHER Trial

This study addresses the question if relevant differences exist between subjects who preserve the HER2 status and those who gain the HER2 positivity when relapsed. 

Scientific Reports
Identification of Flap Endonuclease 1 With Diagnostic and Prognostic Value in Breast Cancer

This study aims to identify the potential value of flap endonuclease 1 as a diagnostic and prognostic marker for breast cancer.

Frontiers in Oncology
No Increase in Breast Cancer Risk With Fertility Treatments

No link between fertility treatment and an increase in the risk for breast cancer has been found in the largest study of the issue to date.

The Promising Effects of Sanguinarine in Triple-Negative Breast Cancer Cells

A natural plant compound called sanguinarine has shown promising anti-cancer effects against cell lines from TNBC patients, according to research from Florida A&M University in Tallahassee. 

Oncology Times - Latest Articles
Platinum Agents Not Recommended as Adjuvant Therapy for Basal Subtype Triple-Negative Breast Cancer

Adjuvant treatment with platinum agents fails to improve outcomes in patients with basal subtype TNBC who had residual invasive disease after neoadjuvant chemotherapy.

Cancer Therapy Advisor
Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy

The EA1131 trial hypothesized that iDFS would not be inferior but improved in patients with basal subtype TNBC treated with adjuvant platinum compared with capecitabine.

Journal of Clinical Oncology
ASCO Releases Rapid Guideline Recommendation Update for Patients With High-Risk, HER2-Negative, Germline BRCA–Mutated Breast Cancer

A new ASCO guideline update recommends offering 1 year of adjuvant olaparib to patients with high-risk, early-stage, HER2- breast cancer and germline BRCA mutations after completion of (neo)adjuvan

The ASCO Post
Adjuvant Platinum vs Capecitabine in Patients With Basal Subtype Triple-Negative Breast Cancer and Residual Disease After Neoadjuvant Chemotherapy

The phase III ECOG-ACRIN EA1131 trial investigates the use of adjuvant platinum vs capecitabine in patients with basal subtype TNBC and residual disease following neoadjuvant chemotherapy.

The ASCO Post
Predicting Response to Endocrine Therapy in ER-Positive Breast Cancer

Hormone therapy is designed to stop the effects of estrogen on the tumor and can be very effective for ER+ breast cancer. 

Oncology Times - Latest Articles
Chemotherapy De-escalation Using an 18F-FDG-PET-based Pathological Response-Adapted Strategy in Patients With HER2+ Early Breast Cancer

Study investigators assess early metabolic responses to neoadjuvant trastuzumab and pertuzumab using 18F-fluorodeoxyglucose and the possibility of chemotherapy de-escalation using...

The Lancet Oncology
Adjuvant Trastuzumab Emtansine vs Paclitaxel/Trastuzumab in Stage I HER2-Positive Breast Cancer

Dr Sara M. Tolaney and colleagues find that adjuvant trastuzumab emtansine results in “excellent” invasive DFS but does not reduce clinically relevant toxicity compared with...

The ASCO Post
Managing HER2-Positive Breast Cancer Amid COVID-19

Although the patient experience has been an important factor in treatment development and selection for HER2+ patients, this has been magnified in the setting of the COVID-19 pandemic. 

Oncology Times - Latest Articles
Improving Prediction of Complete Response in Breast Cancer

Combining a liquid biopsy with MRI significantly improves accuracy for predicting complete response among patients with locally advanced breast cancer who received neoadjuvant chemotherapy.

Oncology Times - Latest Articles
Evolving Strategies in Sequencing for HER2+ MBC Therapy

The landscape for therapies targeting HER2-positive metastatic breast cancer has evolved rapidly in the past few years.

Phase II Trial Correlating Standardized Uptake Value With Pathological Complete Response to Pertuzumab and Trastuzumab in Breast Cancer

Predictive biomarkers to identify patients with HER2+ breast cancer who may benefit from targeted therapy alone are required.

Journal of Clinical Oncology
Inequities in Breast Cancer Screening During the COVID-19 Pandemic

Breast cancer screening took a sizeable hit during the COVID-19 pandemic, according to new research  showing that the number of screening mammograms completed in a large group of women...

The ASCO Post
Margetuximab-cmkb Plus Chemotherapy Prolongs Progression-Free Survival in Heavily Pretreated HER2-Positive Breast Cancer

The phase III SOPHIA trial has shown significantly prolonged PFS with margetuximab-cmkb plus CT vs trastuzumab plus CT in patients with HER2+ breast cancer whose disease had progressed on two or...

The ASCO Post
Carnosol Is a Novel Inhibitor of p300 Acetyltransferase in Breast Cancer

Study investigators report that carnosol induces histone hypoacetylation in MDA-MB-231 and Hs578T breast cancer cells.

Frontiers in Oncology
Evolution to HER2-Low Breast Cancer: Investigating Potential Therapeutics

The finding that breast tumors can evolve to express low HER2 potentially increases the number of patients who can benefit from new investigational agents, typically novel antibody-drug conjugate..

The ASCO Post
Freezing Breast Cancer to Death Avoids Surgery

In the US, cryoablation or freezing tissue to death is a primary treatment option for many cancers. But unlike in Europe, this nonsurgical approach is not approved for breast cancer in the US.

Primary Breast Tumors Often Switch HER2 Status on Relapse

A substantial proportion of primary breast tumors that are HER2 negative (HER2-0) switch to showing HER2-low expression upon relapse, a first-of-its-kind study suggests.

First-Line Pembrolizumab Plus Chemotherapy in PD-L1–Positive Locally Recurrent Triple-Negative Breast Cancer

The addition of pembrolizumab to CT improves PFS among previously untreated patients with locally recurrent inoperable or metastatic TNBC with a PD-L1 expression combined positive score ≥ 10.

The ASCO Post
Better Survival After Lumpectomy Plus RT vs Mastectomy

Overall survival and breast cancer–specific survival are consistently better for women with early breast cancer who are treated with BCS followed by RT compared to women who are treated with Mx...<

Cost-Effectiveness of Adding Ribociclib to Endocrine Therapy for Patients With HR+, HER2- Advanced Breast Cancer Among Premenopausal or Perimenopausal Women

This study evaluates the cost-effectiveness of adding ribociclib to endocrine therapy for pre/perimenopausal women with HR+, HER2- advanced breast cancer from the US payer perspective.

Frontiers in Oncology
Fertility Concerns May Influence Decisions About Endocrine Therapy in Young Women With Breast Cancer

Concerns about fertility often influence how young women with breast cancer approach treatment decisions and are a reason for forgoing or delaying hormone-blocking therapy. 

The ASCO Post

source list reference